Related Experiment Videos
9-Deazaadenosine--a new potent antitumor agent
Abstract:
-Deazaadenosine (9-DAA), a novel purine analog, was found to be a potent inhibitor of the growth of nine different human solid tumor cell lines in vitro and of pancreatic carcinoma (DAN) in antithymocyte serum (ATS)-immunosuppressed mice. In culture, IC50 values ranged from 1.1 to 8.5 X 10(-8)M. Ovarian carcinoma (MR) was the only cell line in which the activity of 9-DAA was potentiated (about 10-fold) by pretreatment with the adenosine deaminase inhibitor 2'-deoxycoformycin (dCF). After incubation of cultured pancreatic DAN cells with 9-DAA (10(-5)M) for 2 hr, a peak appeared in the triphosphate region of HPLC nucleotide profiles that was identified tentatively as 9-deazaATP. Under the same incubation conditions, the incorporation of [3H]uridine into RNA and of [3H]thymidine into DNA was inhibited by 34 and 80% respectively. In vivo studies using ATS-immunosuppressed mice showed that 9-DAA at 0.4 mg/kg/day for 3 consecutive days reduced pancreatic carcinoma (DAN) tumor weights to approximately 50% of untreated controls. The nucleoside transport inhibitor p-nitrobenzyl-6-thioinosine (NBMPR) was shown to selectively protect host tissues from 9-DAA toxicity and, thereby, potentiated the antitumor activity of 9-DAA in vivo at optimal dosages.
Insights
9-deazaadenosine (9-DAA), a novel purine analog, effectively inhibits human solid tumor cell growth in vitro and pancreatic tumors in mice. It shows potential as an anticancer agent, especially when combined with other inhibitors.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Novel purine analog 9-deazaadenosine (9-DAA) exhibits potent anticancer properties.
- Investigating the efficacy and mechanisms of 9-DAA against various human solid tumors.
Purpose of the Study:
- To evaluate the in vitro and in vivo anticancer activity of 9-deazaadenosine.
- To explore the synergistic effects of 9-DAA with adenosine deaminase inhibitors and nucleoside transport inhibitors.
Main Methods:
- In vitro cytotoxicity assays against nine human solid tumor cell lines.
- In vivo studies using antithymocyte serum (ATS)-immunosuppressed mice bearing pancreatic carcinoma (DAN).
- High-performance liquid chromatography (HPLC) for nucleotide profiling and incorporation studies of radiolabeled nucleosides.
Main Results:
- 9-DAA demonstrated potent inhibition with IC50 values ranging from 1.1 to 8.5 X 10(-8)M against tumor cell lines.
- 2'-deoxycoformycin (dCF) potentiated 9-DAA activity against ovarian carcinoma (MR) by approximately 10-fold.
- In vivo, 9-DAA (0.4 mg/kg/day) reduced pancreatic tumor weights by 50%; p-nitrobenzyl-6-thioinosine (NBMPR) enhanced antitumor activity by reducing host toxicity.
Conclusions:
- 9-deazaadenosine is a promising anticancer agent with broad-spectrum activity against human solid tumors.
- Combination therapies involving 9-DAA with dCF or NBMPR may enhance therapeutic efficacy and reduce toxicity.